Susanne Jörg joined Lonza, Switzerland, in 2006 as Head of Pharmaceutical Development, Drug Product Services. Her team is responsible for formulation and process development for customers' projects and related analytical testing, manufacturing of preclinical drug product supplies, process transfer to the GMP manufacturing site, and primary packaging and device functionality testing.
Prior to joining Lonza, Susanne worked for 10 years in leadership roles at Novartis, most recently as Group Head Early Phase Pharmaceutical Development. She was involved into the development of Cosentyx as well as several product IND/IMPD submissions of monoclonal antibodies, recombinant protein, fusion proteins, bioconjugates, antibody fragments, nanobodies, and antibody-drug-conjugates for parenterals for various administration routes. Susanne studied pharmacy and holds a Ph.D from the Ludwig Maximillians University, Munich, Germany. In collaboration with Merck KGaA, Darmstadt (DE), she developed liquid high-concentration mAb formulations, and supported the registration filing of Erbitux®.